Holen Sie sich die Stockscreener-App
454.66
0.12%
2.71
Schlusskurs vom Vortag:
$451.95
Offen:
$450.63
24-Stunden-Volumen:
42,649
Relative Volume:
0.04
Marktkapitalisierung:
$59.53B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,890.48
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
+4.13%
1M Leistung:
-1.73%
6M Leistung:
+67.48%
1J Leistung:
+68.25%
1-Tages-Spanne:
$446.71
$454.27
1-Wochen-Bereich:
$429.00
$455.20
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
454.15 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.85 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.65 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
897.36 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.25 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policies2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Regression analysis insights on Alnylam Pharmaceuticals Inc. performanceJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - newser.com
Wells Fargo Raises Price Target for Alnylam Pharmaceuticals (ALNY) | ALNY Stock News - GuruFocus
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosJuly 2025 News Drivers & Low Drawdown Momentum Trade Ideas - newser.com
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money - Yahoo Finance
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumWeekly Investment Recap & Smart Money Movement Tracker - newser.com
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail
ALNY: Cardiomyopathy launch accelerates growth as pipeline and new tissue programs drive 2030 vision - TradingView
Alnylam at UBS Healthcare: Strategic Insights on Growth and Innovation By Investing.com - Investing.com UK
Transcript : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 10 - MarketScreener
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 19% ROE Better Than Average? - 富途牛牛
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Big Picture & Trade Opportunity Analysis - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrend2025 Trading Recap & Consistent Growth Stock Picks - newser.com
Alnylam (ALNY) Reports Positive Results from HELIOS-B Phase 3 St - GuruFocus
Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study - TipRanks
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New HELIOS-B Data and Upbeat Financial Results - simplywall.st
Alnylam Pharmaceuticals Inc says amyloid regression in 22% of vutrisiran-treated patients - MarketScreener
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM - Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Sahm
A Closer Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Improved Earnings and Raised Revenue Guidance - Yahoo Finance
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Surging Revenue and Raised 2025 Guidance - simplywall.st
Has Alnylam Pharmaceuticals Inc. found a price floorEarnings Beat & AI Enhanced Trading Alerts - newser.com
Alnylam Pharmaceuticals Scores Relative Strength Rating Upgrade - Investor's Business Daily
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.July 2025 Price Swings & High Accuracy Buy Signal Tips - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s future2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboardsBull Run & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-11-09 13:28:49 - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Intraday Action & Safe Entry Trade Reports - Fundação Cultural do Pará
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersTrade Performance Summary & Verified High Yield Trade Plans - newser.com
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver shareholder valueRate Cut & Weekly Sector Rotation Insights - Fundação Cultural do Pará
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Biggest Moves & Short-Term Trading Alerts - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockStock Surge & Stock Portfolio Risk Control - newser.com
Published on: 2025-11-05 12:16:44 - newser.com
Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025? - simplywall.st
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
0.43%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):